Abstract
INTAKE of MPTP (l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine) leads to symptoms of Parkinson's disease and produces degeneration of nigrostriatal dopaminergic neurons in humans, giving rise to the hypothesis that this disorder may be caused by endogenous or environmental toxins1–3. Excitation mediated by dicarboxylic amino acids such as L-glutamate or L-aspartate, has been claimed to be involved in pathogenesis of neurodegenerative disorders4. We therefore sought to determine whether antagonists active at the NMDA or quisqualate subtypes of L-glutamate receptors prevent toxicity of either MPP+ (l-methyl-4-phenyl-pyridinium ion5, the active metabolite of MPTP6) or the selective dopaminergic neurotoxin 6-OHDA in the rat substantia nigra pars compacta. We report here that certain selective NMDA antagonists (AP7, CPP, MK-801)7, but not the preferential quisqualate antagonists CNQX and NBQX,8 provided short-term (up to 24 h) protection against MPP+ toxicity when coadministered into the substantia nigra. Systemic administration of CPP or MK-801 also offered temporary protection for up to 4 h against MPP+ toxicity. Repeated systemic administration of either compound prolonged protection against MPP+ challenge. Repeated administration for at least 24 h also led to permanent protection, still evident 7 days after intranigral administration of MPP+.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Langston, J. W., Ballard, P., Tetrud, J. W. & Irwin, I. Science 219, 979–980 (1983).
Burns, R. S. et al. Proc. natn. Acad. Sci. U.S.A. 80, 4546–4550 (1983).
Bradbury, A. J. et al. Nature 319, 56–57 (1986).
Olney, J. W. In Frontiers in Excitatory Amino Acid Research (eds Cavalheiro, E., Lehmann, J. & Turski, L.) 589–596 (Liss, New York, 1988).
Markey, S. P., Johanessen, J. N., Chiueh, C. C., Burns, R. S. & Herkenham, M. A. Nature 311, 464–467 (1984).
Heikkila, R. E., Manzino, L., Cabbat, F. S. & Duvoisin, R. C. Nature 311, 467–469 (1984).
Olvermann, H. J., Jones, A. W. & Watkins, J. C. Nature 307, 460–462 (1984).
Sheardown, M. J., Nielsen, E. O., Hansen, A. J., Jacobsen, P. & Honore, T. Science 247, 571–574 (1990).
Fallon, J. H. & Loughlin, S. E. In The Rat Nervous System (ed. Paxinos, G.) 353–403 (Academic, Sydney, 1985).
Sonsalla, P. K., Nicklas, W. J. & Heikkila, R. E. Science 243, 398–400 (1989).
Nicklas, W. J., Vyas, I. & Heikkila, R. E. Life Sci. 36, 2503–2508 (1985).
Ramsay, R. R., Salach, J. I. & Singer, T. P. Biochem. biophys. Res. Commun. 134, 743–748 (1986).
Di Monte, D. & Smith, M. T. Rev. Neurosci. 2, 67–82 (1988).
Nowak, L., Bregestovski, P., Ascher, P., Herbet, A. & Prochiantz, A. Nature 307, 462–465 (1984).
Novelli, A., Reilly, J. A., Lysko, P. G. & Henneberry, R. C. Brain Res. 451, 205–212 (1988).
Rothman, S. Science 220, 536–538 (1983).
Irwin, I., DeLanney, L. E., Di Monte, D. & Langston, J. W. Neurosci. Lett. 101, 83–88 (1989).
Johannessen, J. N., Chiueh, C. C., Burns, R. S. & Markey, S. P. Life Sci. 36, 219–224 (1985).
Ohya, Y. et al. Neurosci. Lett. 105, 221–226 (1989).
Chapman, A., Collins, J. F., Meldrum, B. S. & Westerberg, E. Neurosci. Lett. 37, 75–80 (1983).
Compton, R. P., Hood, W. F. & Monahan, J. B. Neurosci. Lett. 84, 339–344 (1988).
Vezzani, A. et al. J. Pharmacol. exp. Ther. 249, 278–283 (1989).
Gibb, W. R. G., Costall, B., Domeney, A. M., Kelly, M. E. & Naylor, R. J. Brain Res. 461, 361–366 (1988).
Sun, C. J. et al. J. neural Transm. 74, 75–86 (1988).
Christie-Pope, B. C., Burns, R. S. & Whetsell, W. O. Expl Neurol. 104, 235–240 (1989).
Calne, D. B., Eisen, A., McGeer, E. & Spencer, P. Lancet ii, 1067–1070 (1986).
Spencer, P. S. et al. Science 237, 517–522 (1987).
Mawdsley, C. & Ferguson, F. R. Lancet ii, 795–801 (1963).
Weiss, J. H. & Choi, D. W. Science 241, 973–975 (1988).
Faden, A. I., Demediuk, P., Panter, S. S. & Vink, R. Science 244, 798–800 (1989).
Olney, J. W. et al. Eur. J. Pharmacol. 142, 319–320 (1987).
Bormann, J. Eur. J. Pharmacol. 166, 591–592 (1989).
Tetrud, J. W. & Langston, J. W. Science 245, 519–522 (1989).
König, J. F. R. & Klippel, R. A. The Rat Brain. A Stereotaxic Atlas of the Forebrain and Lower Parts of the Brain Stem (William and Wilkins, Baltimore, 1963).
Fink, R. P. & Heimer, L. Brain Res. 4, 369–374 (1967).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Turski, L., Bressler, K., Jürgen Rettig, K. et al. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists. Nature 349, 414–418 (1991). https://doi.org/10.1038/349414a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/349414a0
This article is cited by
-
Erythrocytic α-synuclein contained in microvesicles regulates astrocytic glutamate homeostasis: a new perspective on Parkinson’s disease pathogenesis
Acta Neuropathologica Communications (2020)
-
Human Cortex Spheroid with a Functional Blood Brain Barrier for High-Throughput Neurotoxicity Screening and Disease Modeling
Scientific Reports (2018)
-
Sigma-1 receptor deficiency reduces MPTP-induced parkinsonism and death of dopaminergic neurons
Cell Death & Disease (2015)
-
A Nucleoprotein-Enriched Diet Suppresses Dopaminergic Neuronal Cell Loss and Motor Deficit in Mice with MPTP-Induced Parkinson’s Disease
Journal of Molecular Neuroscience (2015)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.